Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Introduction: This phase 2 study evaluated magrolimab+venetoclax (VEN)+azacitidine (AZA) in untreated, unfit acute myeloid leukaemia (AML) and magrolimab+mitoxantrone+etoposide+cytarabine in relapsed/refractory (R/R) AML.
Methods: Endpoints included complete remission rate (CRR), overall response rate (ORR), overall survival (OS) and safety.
Results: Eighteen and 36 patients were enrolled into the unfit and R/R AML arms, respectively. CRR was 38.9% and 25.0%, ORR was 66.7% and 38.9%, and median OS was 15.3 and 10.5 months in the unfit AML and R/R AML arms, respectively. No dose-limiting toxicities or magrolimab-related deaths occurred.
Conclusion: Magrolimab was safely combined with existing AML therapies with no new safety signals.
Clinical Trial Registration: This trail was registered at www.clinicaltrials.gov as NCT04778410.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12073901 | PMC |
| http://dx.doi.org/10.1002/jha2.70051 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Unraveling complex karyotype clonal architecture: co-existing double TP53 mutations alongside DNMT3A, TET2, and NF1 mutations - a case study.
Cancer Genet
August 2025
Clinical Hematology and BMT Unit, Bahrain Oncology Center, Road 2835, Block 228, P.O. Box 24343, Busaiteen, Kingdom of Bahrain. Electronic address:
Complex chromosomal changes in Acute Myeloid Leukemia (AML) are highly heterogeneous, with disease progression shaped by both the number and nature of abnormalities. Rarely do, multiple unrelated clones with independent chromosomal changes coexist at diagnosis. Present study showcases a comprehensive characterization of two cytogenetically distinct complex clones in AML, driven by non-cyclic and chromoplexy mechanisms, highlighting their co-existence with key molecular alterations (TP53, NF1, DNMT3A, TET2) along with their potential contribution to clonal evolution.
View Article and Find Full Text PDFA multi-omics recovery factor predicts long COVID in the IMPACC study.
J Clin Invest
September 2025
The University of Texas at Austin, Austin, United States of America.
Background: Following SARS-CoV-2 infection, ~10-35% of COVID-19 patients experience long COVID (LC), in which debilitating symptoms persist for at least three months. Elucidating biologic underpinnings of LC could identify therapeutic opportunities.
Methods: We utilized machine learning methods on biologic analytes provided over 12-months after hospital discharge from >500 COVID-19 patients in the IMPACC cohort to identify a multi-omics "recovery factor", trained on patient-reported physical function survey scores.
Background: Nucleophosmin 1 (NPM1) mutations represent one of the most frequent genetic alterations in acute myeloid leukemia (AML). However, the prognostic significance of concurrent molecular abnormalities and clinical features in NPM1-mutated AML remains to be fully elucidated.
Methods: We retrospectively analyzed 73 adult AML patients with NPM1 mutations.
Background: This study aimed to identify the diagnostic and prognostic ability of serum miR-411-3p in patients with acute myeloid leukemia (AML).
Methods: Blood samples were collected from 60 AML patients and 60 healthy controls to measure serum miR-411-3p and thereafter discuss its potential clinical value.
Results: Serum miR-411-3p was decreased in AML patients and was even lower in those with M4/M5 subtypes or high white blood cell count or adverse cytogenetic risk.
Background: Angioimmunoblastic T-cell lymphoma (AITL) is a rare and aggressive form of peripheral T-cell lymphoma, accounting for 1 - 2% of non-Hodgkin lymphomas. Diagnosis is challenging, and there is no established standard first-line treatment. This case report highlights a rare progression from AITL to therapy-related acute myeloid leukemia (AML-pCT) following cytotoxic chemotherapy.
View Article and Find Full Text PDF